Full Text View
Tabular View
Study Results
Related Studies
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
This study is ongoing, but not recruiting participants.
Study NCT00050778   Information provided by Genzyme

First Received on December 19, 2002.   Last Updated on July 13, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
interferon beta-1a (Rebif®)
alemtuzumab
Additional drug interventions recognized in this trial
Antibodies, Neoplasm
Campath 1G
Interferon beta 1a
Interferon-beta
Interferons
More general drug interventions related to this trial
Adjuvants, Immunologic
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Genzyme
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services